HALOZYME THERAPEUTICS, INC.
HALOUS売上高
$1.4B
百万USD
営業利益
$469M
百万USD
純利益
$317M
百万USD
ROE
649.2%
最新FY
EPS
$2.56
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $89M | $28M | $0.19 |
| FY2021 | Q2 | $136M | $91M | $0.62 |
| FY2021 | Q3 | $116M | $217M | $1.48 |
| FY2021 | FY | $443M | $403M | $2.74 |
| FY2022 | Q1 | $117M | $60M | $0.43 |
| FY2022 | Q2 | $152M | $23M | $0.16 |
| FY2022 | Q3 | $209M | $62M | $0.44 |
| FY2022 | FY | $660M | $202M | $1.44 |
| FY2023 | Q1 | $162M | $40M | $0.29 |
| FY2023 | Q2 | $221M | $75M | $0.56 |
| FY2023 | Q3 | $216M | $82M | $0.61 |
| FY2023 | FY | $829M | $282M | $2.10 |
| FY2024 | Q1 | $196M | $77M | $0.60 |
| FY2024 | Q2 | $231M | $93M | $0.72 |
| FY2024 | Q3 | $290M | $137M | $1.05 |
| FY2024 | FY | $1.0B | $444M | $3.43 |
| FY2025 | Q1 | $265M | $118M | $0.93 |
| FY2025 | Q2 | $326M | $165M | $1.33 |
| FY2025 | Q3 | $354M | $175M | $1.43 |
| FY2025 | FY | $1.4B | $317M | $2.56 |
| FY2026 | Q1 | $377M | $150M | $1.22 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | - | $196M | $268M | $443M | $660M | $829M | $1.0B | $1.4B |
| 営業利益 | $-83M | $81M | $-69M | $-68M | $144M | $276M | $268M | $338M | $551M | $469M |
| 純利益 | $-103M | $63M | $-80M | $-72M | $129M | $403M | $202M | $282M | $444M | $317M |
| 総資産 | $262M | $520M | $440M | $566M | $580M | $1.1B | $1.8B | $1.7B | $2.1B | $2.5B |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $-32M | $208M | $249M | $92M | $151M | $197M | $170M | $84M | $364M | $49M |
| 営業CF | $-50M | - | - | $-85M | $55M | $299M | $240M | $389M | $479M | $652M |
| EPS | - | $0.45 | $-0.56 | $-0.50 | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
| BPS | $-0.25 | $1.46 | $1.72 | $0.66 | $1.12 | $1.43 | $1.25 | $0.66 | $2.95 | $0.41 |
| ROE | 317.2% | 30.2% | -32.3% | -78.7% | 85.5% | 204.5% | 119.0% | 336.0% | 122.1% | 649.2% |